Attached files
| file | filename |
|---|---|
| EX-21.1 - EX-21.1 - Nurix Therapeutics, Inc. | d903927dex211.htm |
| EX-10.11 - EX-10.11 - Nurix Therapeutics, Inc. | d903927dex1011.htm |
| EX-10.10 - EX-10.10 - Nurix Therapeutics, Inc. | d903927dex1010.htm |
| EX-10.9 - EX-10.9 - Nurix Therapeutics, Inc. | d903927dex109.htm |
| EX-10.8 - EX-10.8 - Nurix Therapeutics, Inc. | d903927dex108.htm |
| EX-10.2 - EX-10.2 - Nurix Therapeutics, Inc. | d903927dex102.htm |
| EX-10.1 - EX-10.1 - Nurix Therapeutics, Inc. | d903927dex101.htm |
| EX-4.2 - EX-4.2 - Nurix Therapeutics, Inc. | d903927dex42.htm |
| EX-4.1 - EX-4.1 - Nurix Therapeutics, Inc. | d903927dex41.htm |
| EX-3.3 - EX-3.3 - Nurix Therapeutics, Inc. | d903927dex33.htm |
| EX-3.1 - EX-3.1 - Nurix Therapeutics, Inc. | d903927dex31.htm |
| S-1 - S-1 - Nurix Therapeutics, Inc. | d903927ds1.htm |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Registration Statement on Form S-1 of Nurix Therapeutics, Inc. of our report dated May 5, 2020 relating to the financial statements of Nurix Therapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers LLP
San Jose, California
July 2, 2020